Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a sterile solution for intravenous and subcutaneous use. It stimulates neutrophil production and is used to reduce the duration of neutropenia in patients undergoing chemotherapy, bone‑marrow transplantation, or with congenital neutrophil disorders.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) acts on the hematopoietic system to support neutrophil recovery in several clinical settings.

- Chemotherapy‑induced neutropenia: shortens the period of low neutrophil counts and reduces infection risk. - Aplastic anemia: promotes neutrophil production in patients with bone‑marrow failure. - Bone marrow transplantation: enhances engraftment and accelerates neutrophil recovery post‑transplant. - Congenital neutropenia: maintains adequate neutrophil levels in inherited neutrophil disorders.

Neupogen may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are essential.

Common Side Effects: - Bone pain: often mild to moderate, typically in the limbs or back. - Injection site reactions: redness, swelling, or discomfort at the administration site. - Fever: low‑grade temperature elevations. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring immediate medical attention. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Severe allergic reactions: hives, swelling, or anaphylaxis. - Leukocytosis: excessively high white‑blood cell counts. - Capillary leak syndrome: rapid fluid shift causing low blood pressure. - Thromboembolic events: blood clots in veins or arteries.

Before using Neupogen, consider the following safety measures.

- Renal impairment: adjust monitoring as reduced clearance may affect exposure. - Sickle cell disease: observe for vaso‑occlusive crises. - Prior splenectomy: increased vigilance for splenic complications. - Concurrent chemotherapy: coordinate timing to avoid overlapping toxicities. - Pediatric use: dose and response may differ; follow specialist guidance. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Neupogen can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Corticosteroids: may blunt neutrophil response to filgrastim. - Chemotherapeutic agents with prolonged myelosuppression: can counteract the intended neutrophil recovery.

Moderate Interactions (Monitor Closely): - Antimicrobial agents (e.g., quinolones): may increase risk of bone pain. - Immunosuppressants (e.g., cyclosporine): monitor for additive effects on blood counts. - Live vaccines: reduced efficacy; consider timing of vaccination relative to filgrastim administration.